SC18 from Idea to Industry: A History of CAR T-Cells to Where we are Today, and the Challenges of Commercialization
24th Internnational Molecular Medicine Tri-Conference 2017
Ronald P. Dudek, President, Living Pharma, Inc.
Yeong (Christopher) Choi, Ph.D., Assistant Professor, Oncology; Member, Center for Immunotherapy; Director, cGMP Therapeutic Cell Production Facility, Roswell Park Cancer Institute
Cenk Sumen, Ph.D., Senior Manager, Business Development, PCT, a Caladrius company
The following topics will be covered:
A Review of the Chimeric Antigen Receptor (CAR)
- History
- Drivers
- Designs
Intellectual Property
- First Blood: CD-19 CAR T-Cell Patent Litigation
- Bead Reagent Tie-Ups
Types
- Autologous Products
- Allogeneic Products
- Universal Products
Manufacturing
- Reagents and Devices
- Processes
- Facilities
- Academic Manufacturers
- Industrial Manufacturers
Cell Therapy: The Importance of Current Good Manufacturing Practices and Quality
Yeong (Christopher) Choi, Ph.D., Assistant Professor, Oncology; Member, Center for Immunotherapy; Director, cGMP Therapeutic Cell Production Facility, Roswell Park Cancer Institute
Successful Manufacturing of CAR T-Cell Therapies: Challenges and Opportunities
Cenk Sumen, Ph.D., Senior Manager, Business Development, PCT, a Caladrius company
Markets for Anti-CD19 CAR T-Cells
- Acute Lymphoblastic Leukemia
- Diffuse Large B-Cell Lymphoma
Race to Approval
- Regulatory Filings
- Projected Product Launch Dates
February 19 - 24, 2017
Moscone South Convention Center
San Francisco CA